Description
It is a hyaluronan-based viscosupplement, and its hyaluronan is ultra-pure and referred to as HYADD 4. The company behind Hymovis, Fidia Farmaceutici S.p.A., uses unique processing techniques to increase the viscosity, elasticity, and residence time of Hymovis’s hyaluronan without the use of any chemical crosslinking. Hymovis is indicated for use as a form of viscosupplementation for patients with knee osteoarthritis that fail to respond or respond unsatisfactorily to conservative medical treatment and physiotherapy. Its treatment course is two injections for one knee; the second injection should come a week after the first. Hymovis is a prescription-only medication, and its injection should only be performed by a trained and qualified medical professional.
